309 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Recruiting Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Condition: Neoplasms by Site
Interventions: Biological: BMS-986016;   Biological: BMS-936558
22 Completed PD-1/PD-L1 Pathway Study on Septic Patients
Condition: Sepsis
Intervention:
23 Not yet recruiting Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
Conditions: Lymphoma;   Lung Cancer
Intervention: Biological: JS-001
24 Recruiting A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
Condition: Advanced Melanoma
Intervention: Drug: Pembrolizumab
25 Recruiting Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
Conditions: Breast Neoplasms;   Bone Neoplasms
Interventions: Radiation: Stereotactic Ablative Body Radiosurgery (SABR);   Drug: MK-3475
26 Recruiting Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Condition: Melanoma
Interventions: Drug: ipilimumab;   Drug: nivolumab
27 Active, not recruiting A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Condition: Advanced Solid Tumors
Interventions: Drug: PF-05082566;   Drug: MK-3475
28 Not yet recruiting Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
Conditions: Carcinoma, Non-small-cell Lung;   Mesothelioma;   Pancreatic Neoplasms
Interventions: Drug: Defactinib;   Drug: Pembrolizumab
29 Active, not recruiting AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma
Interventions: Drug: AMP-224;   Radiation: Stereotactic Body Radiation Therapy(SBRT);   Drug: Cyclophosphamide
30 Active, not recruiting A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: Lomustine;   Drug: Placebo;   Radiation: Radiotherapy;   Drug: SOC;   Drug: Temozolomide
31 Recruiting Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Melanoma
Intervention: Drug: Pembrolizumab and Ipilimumab combination
32 Recruiting A Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
Condition: CANCER,NOS
Interventions: Drug: Lirilumab;   Drug: Nivolumab
33 Not yet recruiting Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
Conditions: Melanoma and Other Malignant Neoplasms of Skin;   Metastatic Melanoma
Interventions: Drug: Azacitidine;   Drug: Pembrolizumab
34 Recruiting Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
Condition: Metastatic Melanoma
Interventions: Biological: blood sampling;   Drug: Nivolumab
35 Recruiting Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Nivolumab
36 Active, not recruiting Phase I Biomarker Study (BMS-936558)
Condition: Renal Cell Carcinoma
Intervention: Drug: BMS-936558 (Anti-PD-1)
37 Recruiting Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Condition: Melanoma
Interventions: Drug: MK-3475;   Drug: Peginterferon alfa-2b
38 Active, not recruiting PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Condition: Renal Cell Carcinoma
Interventions: Drug: CT-011;   Biological: DC/RCC fusion vaccine
39 Recruiting Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
Condition: Melanoma
Interventions: Biological: 6MHP;   Drug: Pembrolizumab
40 Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Conditions: Acute Myelogenous Leukemia;   AML
Interventions: Biological: DC AML Vaccine;   Drug: CT-011

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years